Table 2 Transplant-related events univariate analysis
Characteristic (%) | ATG (N = 363) | CD34 (N = 162) | p |
|---|---|---|---|
OS at 2 years, months (95% CI) | 69.9 (58.5–69.4) | 67.6 (60.3–74.8) | 0.31 |
LFS at 2 years, months (95% CI) | 57.9 (52.4–63.4) | 61.0 (53.4–68.5) | 0.29 |
Cumulative incidence of NRM at 2 years (95% CI) | 12.1 (8.9–15.9) | 17.4 (12.0–23.6) | 0.16 |
Cumulative incidence of relapse at 2 years (95% CI) | 30.0 (24.9–35,2) | 21.6 (15.6–28.3) | 0.03 |
Cumulative incidence of grade II–IV aGVHD at 100 days (95% CI) | 21.2 (17.1–25.6) | 11.3 (7.0–16.8) | 0.006 |
Cumulative incidence of grade III–IV aGVHD at 100 days (95% CI) | 6.2 (4–9.1) | 1.3 (0.2–4.1) | 0.01 |
Cumulative incidence of cGVHD at 1 year (95% CI) | 27.6 (22.8–32.6) | 2.5 (0.8–5.8) | < 0.0001 |
Cumulative incidence of extensive cGVHD at 1 year (95% CI) | 11.3 (8.0–15.1) | 2.5 (0.8–5.8) | 0.001 |
Cumulative incidence of GRFS at 2 years (95% CI) | 47.0 (41.4–52.5) | 59.1 (51.5–66.7) | 0.003 |
Cause of death | |||
GVHD | 14 (12%) | 5 (10%) | 0.36 |
Infections | 19 (17%) | 16 (30%) | |
Other | 20 (18%) | 7 (14%) | |
Relapse/progression | 59 (53%) | 24 (46%) | |